Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New biosimilar guidance from EMA allows non-EU comparator

This article was originally published in Scrip

Executive Summary

The revised version of the European Medicines Agency's general guideline on biosimilar medicines has now been published, complete with a number of changes from the original, including the possibility of using a non-EU comparator drug in order to avoid unnecessary clinical testing, and of extrapolating indications in certain cases without clinical data.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC026783

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel